Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 97 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Multiparametric MRI Clear all

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Osteosarcoma, Paget's Disease, Ewing Sarcoma
Interventions: DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 13 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Prostate Cancer
Interventions: MRI imaging; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bladder Cancer, Urinary Bladder Neoplasm, Urologic Neoplasms, Neoplasms, Urinary Bladder Diseases
Interventions: Fiducial marker placement, Multiparametric MRI (mpMRI); Procedure · Diagnostic Test
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Prostate Cancer Stage I AJCC V6, Prostate Cancer Stage II, Prostate Cancer Stage III
Interventions: Contrast-Enhanced Ultrasound, High-Intensity Focused Ultrasound, Laboratory Biomarker Analysis, Multiparametric Magnetic Resonance Imaging, Radical Prostatectomy; Procedure · Device · Other
Lead sponsor: University of Southern California; Other
Eligibility: 40 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Renal Transplant Rejection
Interventions: Magnetic Resonance Imaging; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
Interventions: rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18; Radiation · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Diffusion Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging; Procedure
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 4
States / cities: Iowa City, Iowa • Royal Oak, Michigan • Portland, Oregon + 1 more

Conditions: High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer, Prostate Cancer
Interventions: Blood collection; Other
Lead sponsor: Angle plc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Bala-Cynwyd, Pennsylvania • Pottstown, Pennsylvania

Conditions: Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 10
States / cities: Northridge, California • Aurora, Colorado • Denver, Colorado + 7 more

Conditions: IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN)
Interventions: atrasentan; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Spine Health, Spine Injuries and Disorders, Spine Degeneration, Whole Body Vibration
Interventions: Water; Other
Lead sponsor: Milwaukee VA Medical Center; Federal
Eligibility: 20 Years to 45 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Prostate Cancer
Interventions: RSI MRI; Diagnostic Test
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 4
States / cities: San Diego, California • San Francisco, California • Boston, Massachusetts + 1 more

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: SIMRT, HTIMRT; Radiation
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 85 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Portal Hypertension, Clinically Significant Portal Hypertension
Interventions: mpMRI, ARFI US; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Uronav guided biopsy, Magnetic resonance imaging; Device
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer
Interventions: MRI examination; Other
Lead sponsor: Radboud University Medical Center; Other
Eligibility: Male only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 2
States / cities: Los Angeles, California • Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: FTLEAD, Ultra-Short-Term Androgen Deprivation Therapy with Relugolix, HypoLEAD, ADT Standard of Care; Radiation · Drug
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 85 Years · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer, Triple-negative Breast Cancer
Interventions: Tempus assay, Advanced pathology 1, Advanced pathology 2; Other
Lead sponsor: Laura Kennedy; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Prostate Cancer
Interventions: Goserelin, Enzalutamide, mpMRI; Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: multi-parametric MRI(MP-MRI), dynamic contrast-enhanced MRI (DCE), biopsy; Device · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Prostate Cancer
Interventions: 68-Ga RM2., 68-Ga PSMA11, PET/MRI; Drug · Device
Lead sponsor: Andrei Iagaru; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Prostate Cancer
Interventions: SBRT to whole prostate, IMRT followed by mpMRI guided SBRT boost with SIB to intraprostatic lesions; Radiation
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2
Interventions: LiverMultiscan; Device
Lead sponsor: Perspectum; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Sarasota, Florida

Search by objective public record fields.

Improving Cancer Foci Detection in Prostate Cancer Using Multiparametric MRI/MRS

Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma

MRI for Assessing Prostate Cancer Response

Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy

High-Intensity Focused Ultrasound in Treating Participants With Intermediate and High-risk Prostate Cancer

Multi-Parametric MRI for Renal Transplantation

Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

Quantitative MRI Assessment of Breast Cancer Therapy Response

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)

Occupational Exposure to Whole Body Vibration Among U.S. Military Veterans: Acute and Chronic Contributions to Musculoskeletal Disorders and Spine-Area Pain

ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer

Hypofractionated Image-Guided Radiotherapy For Prostate Cancer: The HEIGHT Trial

Assessment of Portal Hypertension With Multiparametric MRI

Pilot Study Evaluating the Role of Histopathology Correlation in Treatment Planning

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

The University of Miami Adapt (UAdapt) Trial

Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy

HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

MRI Guided SBRT for Localized Prostate Cancer

Multi-Parametric MRI Assessment of the Liver in Diabetic Volunteers (Partners Registry)